Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
Background Ruxolitinib, a Janus kinase 1 (JAK1)/JAK2 inhibitor, plus capecitabine improved overall survival (OS) vs capecitabine in a subgroup analysis of patients with metastatic pancreatic cancer and systemic inflammation (C-reactive protein [CRP] >13 mg/dL) in the randomized phase II RECAP study. We report results from two randomized phase III studies, JANUS 1 (NCT02117479) and JANUS 2 (NCT02119663). Patients and Methods Adults with advanced/metastatic pancreatic cancer, one prior chemotherapy regimen and CRP >10 mg/L were randomized 1:1 (stratified by modified Glasgow Prognostic Score [1 vs 2] and Eastern Cooperative Oncology Group performance status [0/1 vs 2]) to 21-day cycles of ruxolitinib 15 mg twice daily plus capecitabine 2000 mg/m2/day (Days 1–14) or placebo plus capecitabine. The primary endpoint was OS. Results Both studies were terminated following a planned interim futility/efficacy analysis of JANUS 1. Overall, 321 and 86 patients were randomized in JANUS 1 (ruxolitinib: n = 161; placebo: n = 160) and JANUS 2 (ruxolitinib: n = 43; placebo: n = 43). There was no significant difference in OS or progression-free survival (PFS) between treatments in JANUS 1 (OS: hazard ratio [HR], 0.969, 95% confidence interval [CI], 0.747–1.256; PFS: HR, 1.056; 95% CI, 0.827–1.348) or JANUS 2 (OS: HR, 1.584; 95% CI, 0.886–2.830; PFS: HR, 1.166; 95% CI, 0.687–1.978). The most common hematologic adverse event was anemia. No new safety signals with ruxolitinib or capecitabine were identified. Conclusions Ruxolitinib plus capecitabine was well tolerated in refractory pancreatic cancer patients; this combination did not improve survival.
KeywordsClinical trial JAK1 protein tyrosine kinase JAK2 protein tyrosine kinase Pancreatic neoplasms
The authors wish to thank the patients and their families, the investigators, and the site personnel who participated in this study. This study was sponsored by Incyte Corporation (Wilmington, DE, USA). Medical writing assistance was provided by Sneha D’Silva, MD, on behalf of Evidence Scientific Solutions Inc. (Philadelphia, PA, USA), and funded by Incyte.
Conception/design of the work: Hurwitz, Van Cutsem, Bendell, Hidalgo, Li, Garrido, Macarulla, Sahai, Sama, Greeno, Yu, Verslype, Clark, O’Reilly.
Acquisition of data: Hurwitz, Van Cutsem, Bendell, Hidalgo, Li, Garrido, Macarulla, Sahai, Sama, Greeno, Yu, Verslype, O’Reilly.
Data analysis and interpretation: Dawkins, Walker, Clark.
Writing, review, and revision of the manuscript: All authors.
Final approval of the manuscript: All authors.
This study was sponsored by Incyte Corporation (Wilmington, DE, USA).
Compliance with ethical standards
Conflicts of interest
Hurwitz: Honoraria – Genentech/Roche, Lilly/ImClone; Consulting or advisory role – Acceleron Pharma, Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Incyte, Lilly, Novartis, OncoMed, TRACON Pharma; Research funding – Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), Lilly (Inst), Macrogenics (Inst), NCI (Inst), Novartis (Inst), Regeneron (Inst), TRACON Pharma (Inst); Employment – Genentech/Roche as of 23 October 2017. Van Cutsem: Research funding – Amgen (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Celgene (Inst), Ipsen (Inst), Lilly (Inst), Merck Serono (Inst), Novartis (Inst), Roche (Inst), Sanofi (Inst). Bendell: Research funding – Incyte. Sahai: Consulting – Celgene, Halozyme, NewLink; Research funding – Agios (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Incyte (Inst). Sama: Honoraria – OncoPlex Diagnostics; Research funding – Bristol-Myers Squibb (Inst), Incyte (Inst), MedImmune (Inst), OncoMed (Inst), Precision Biologics (Inst); Employment – Bristol-Myers Squibb (Inst) as of March 20, 2017. Yu: Consulting or advisory role – Celgene, Merck Serono, Merrimack. Dawkins, Walker, Clark: Employment – Incyte; Stock and other ownership interests – Incyte. O’Reilly: Consulting or advisory role – Aduro Biotech, Astellas Pharma (Inst), Celgene, Celsion (Inst), Cipla, Exelixis (Inst), Gilead Sciences, Hexal (Inst), IntegraGen (Inst), Jennerex (Inst), Lilly (Inst), MedImmune, Merrimack, Novartis (Inst), Pharmacyclics, Sanofi, Silenseed, Vicus Therapeutics; Research funding – AstraZeneca/MedImmune (Inst), Bristol-Myers Squibb (Inst), Celgene (Inst), Immunomedics (Inst), Incyte (Inst), Momenta Pharmaceuticals (Inst), Myriad Genetics (Inst), OncoMed (Inst), Polaris (Inst), Sanofi (Inst). Hidalgo, Li, Garrido, Macarulla, Greeno, Verslype: Nothing to disclose.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 2.NCCN clinical practice guidelines in oncology: Pancreatic adenocarcinoma. Version 2.2017. National Comprehensive Cancer Network website http://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. Accessed 16 August 2017
- 4.Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557. https://doi.org/10.1016/S0140-6736(15)00986-1 CrossRefPubMedGoogle Scholar
- 5.ONIVYDE® (irinotecan liposome injection) [package insert] (2015) Cambridge, Merrimack Pharmaceuticals, IncGoogle Scholar
- 6.Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, Caulder E, Wen X, Li Y, Waeltz P, Rupar M, Burn T, Lo Y, Kelley J, Covington M, Shepard S, Rodgers JD, Haley P, Kantarjian H, Fridman JS, Verstovsek S (2010) Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115:3109–3117. https://doi.org/10.1182/blood-2009-04-214957 CrossRefPubMedPubMedCentralGoogle Scholar
- 7.JAKAVI® (ruxolitinib) [summary of product characteristics] (2016) Camberley, UK, Novartis Europharm Limited. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002464/WC500133223.pdf. Accessed 8 May 2017
- 8.JAKAFI® (ruxolitinib) [package insert] (2016) Wilmington, DE, Incyte Corporation. http://www.jakafi.com/pdf/prescribing-information.pdf. Accessed 8 May 2017
- 9.Gore J, Craven KE, Wilson JL, Cote GA, Cheng M, Nguyen HV, Cramer HM, Sherman S, Korc M (2015) TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis. Oncotarget 6:7504–7521. https://doi.org/10.18632/oncotarget.3233 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Koblish HK, Hansbury M, Wang L-CS, Yang G, Huang T, Xue C-B, Li Y-L, Yue E, Combs A, Yao W, Huber R, Scherle P (2015) Novel immunotherapeutic activity of JAK and PI3Kδ inhibitors in a model of pancreatic cancer [abstract]. Cancer Res 75:1336. https://doi.org/10.1158/1538-7445.am2015-1336 CrossRefGoogle Scholar
- 11.Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Algül H (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 19:456–469. https://doi.org/10.1016/j.ccr.2011.03.009 CrossRefPubMedGoogle Scholar
- 12.Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, Tuli R, Hendifar AE (2014) Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Front Physiol 5(88). https://doi.org/10.3389/fphys.2014.00088
- 14.Salmiheimo A, Mustonen H, Stenman U-H, Puolakkainen P, Kemppainen E, Seppänen H, Haglund C (2016) Systemic inflammatory response and elevated tumour markers predict worse survival in resectable pancreatic ductal adenocarcinoma. PLoS One 11:e0163064. https://doi.org/10.1371/journal.pone.0163064 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS (2015) Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 33:4039–4047. https://doi.org/10.1200/JCO.2015.61.4578
- 18.Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L (2002) Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol 20:2229–2239. https://doi.org/10.1200/JCO.2002.07.093 CrossRefPubMedGoogle Scholar
- 21.Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simionato F, Silvestris N, Brunetti O, Leone F, Marino D, Santini D, Dell'Aquila E, Zeppola T, Puzzoni M, Scartozzi M (2017) Second-line chemotherapy for advanced pancreatic cancer: which is the best option? Crit Rev Oncol Hematol 115:1–12. https://doi.org/10.1016/j.critrevonc.2017.03.025
- 23.Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, Imrie CW, Carter R, McKay CJ, McMillan DC (2011) A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol 18:2318–2328. https://doi.org/10.1245/s10434-011-1560-3 CrossRefPubMedGoogle Scholar
- 24.Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S, Kawakubo K, Kawakami H, Sakamoto N (2017) Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol 8:566–571. https://doi.org/10.21037/jgo.2017.02.02 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Wörmann SM, Song L, Ai JY, Diakopoulos KN, Kurkowski MU, Görgülü K, Ruess D, Campbell A, Doglioni C, Jodrell D, Neesse A, Demir IE, Karpathaki AP, Barenboim M, Hagemann T, Rose-John S, Sansom O, Schmid RM, Protti MP, Lesina M, Algül H (2016) Loss of P53 function activates JAK2-STAT3 signaling to promote pancreatic tumor growth, stroma modification, and gemcitabine resistance in mice and is associated with patient survival. Gastroenterology 151:180–193. https://doi.org/10.1053/j.gastro.2016.03.010 CrossRefPubMedGoogle Scholar
- 31.von Manstein V, Yang CM, Richter D, Delis N, Vafaizadeh V, Groner B (2013) Resistance of cancer cells to targeted therapies through the activation of compensating signaling loops. Curr Signal Transduct Ther 8:193–202. https://doi.org/10.2174/1574362409666140206221931
- 32.Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:819–829. https://doi.org/10.1056/NEJMoa1604958 CrossRefPubMedPubMedCentralGoogle Scholar